CAR-T cells targeting IL-1RAP produced in a closed semiautomatic system are ready for the first phase I clinical investigation in humans.
Fiche publication
Date publication
février 2023
Journal
Current research in translational medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Dr FERRAND Christophe, Dr DESCHAMPS Marina
Tous les auteurs :
Nicod C, da Rocha MN, Warda W, Roussel X, Haderbache R, Seffar E, Trad R, Bouquet L, Goncalves M, Bosdure L, Laude MC, Guiot M, Ferrand C, Deschamps M
Lien Pubmed
Résumé
The use of chimeric antigen receptor (CAR)-T cells has demonstrated excellent results in B-lymphoid malignancies. The Advanced Therapy Medicinal Products (ATMP) status and good manufacturing practice (GMP) of CAR-T cells require particular conditions of production performed in a pharmaceutical establishment. Our team developed a new medical drug candidate for acute myeloid leukemia (AML), a CAR targeting interleukin-1 receptor accessory protein (IL-1RAP) expressed by leukemia stem cells, which will need to be evaluated in a phase I-IIa clinical trial. During the preclinical development phase, we produced IL-1RAP CAR-T cells in a semi-automated closed system (CliniMACSࣨ Prodigy) using research grade lentiviral particles.
Mots clés
Acute myeloid leukemia, CliniMACS Prodigy™, Closed semi-automated system, IL-1RAP, Preclinical CAR-T cells
Référence
Curr Res Transl Med. 2023 02 4;71(2):103385